Skip to main content
SpringerLink
Log in

Splice Variants of MDM2 in Oncogenesis

  • Chapter
  • First Online:
Mutant p53 and MDM2 in Cancer

Part of the book series: Subcellular Biochemistry ((SCBI,volume 85))

Abstract

Many types of human cancers overexpress MDM2 protein. A common characteristic among these cancers is an associated increase in mdm2 splice variants. Provided here is a comprehensive list, based on a literature review, of over 70 mdm2 variants. These variants are grouped according to in-frame versus out-of-frame status and their potential (or ability) to be translated into isoform proteins. We describe the putative functions for these mdm2 splice variant mRNAs, as well as the mechanistic drivers associated with increased mdm2 transcription and splicing. The paradoxical signal transduction functions of the most commonly studied variants mdm2-a,-b and -c are addressed for their outcomes in the presence and absence of wild-type p53. These outcomes vary from tumor promotion to growth arrest. Finally, we present issues in the detection of endogenous MDM2 protein and how many of the antibodies commonly used to detect MDM2 do not present a full picture of the cellular representation of the isoform proteins. This review provides a focusing lens for individuals interested in learning about the complexities of mdm2 mRNAs and their protein isoforms as well as the roles MDM2 isoforms may play in cancer progression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jeyaraj S, O’Brien DM, Chandler DS (2009) MDM2 and MDM4 splicing: an integral part of the cancer spliceome. Front Biosci 14:2647–2656, doi:3402 [pii]

    Article  CAS  Google Scholar 

  2. Bartel F, Taubert H, Harris LC (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2(1):9–15

    Article  CAS  PubMed  Google Scholar 

  3. Tilgner H, Knowles DG, Johnson R, Davis CA, Chakrabortty S, Djebali S, Curado J, Snyder M, Gingeras TR, Guigo R (2012) Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional in the human genome but inefficient for lncRNAs. Genome Res 22(9):1616–1625. doi:10.1101/gr.134445.111

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, Epstein CB, Frietze S, Harrow J, Kaul R, Khatun J, Lajoie BR, Landt SG, Lee BK, Pauli F, Rosenbloom KR, Sabo P, Safi A, Sanyal A, Shoresh N, Simon JM, Song L, Trinklein ND, Altshuler RC, Birney E, Brown JB, Cheng C, Djebali S, Dong X, Ernst J, Furey TS, Gerstein M, Giardine B, Greven M, Hardison RC, Harris RS, Herrero J, Hoffman MM, Iyer S, Kelllis M, Kheradpour P, Lassman T, Li Q, Lin X, Marinov GK, Merkel A, Mortazavi A, Parker SC, Reddy TE, Rozowsky J, Schlesinger F, Thurman RE, Wang J, Ward LD, Whitfield TW, Wilder SP, Wu W, Xi HS, Yip KY, Zhuang J, Bernstein BE, Green ED, Gunter C, Snyder M, Pazin MJ, Lowdon RF, Dillon LA, Adams LB, Kelly CJ, Zhang J, Wexler JR, Good PJ, Feingold EA, Crawford GE, Dekker J, Elinitski L, Farnham PJ, Giddings MC, Gingeras TR, Guigo R, Hubbard TJ, Kellis M, Kent WJ, Lieb JD, Margulies EH, Myers RM, Starnatoyannopoulos JA, Tennebaum SA, Weng Z, White KP, Wold B, Yu Y, Wrobel J, Risk BA, Gunawardena HP, Kuiper HC, Maier CW, Xie L, Chen X, Mikkelsen TS, Gillespie S, Goren A, Ram O, Zhang X, Wang L, Issner R, Coyne MJ, Durham T, Ku M, Truong T, Eaton ML, Dobin A, Lassmann T, Tanzer A, Lagarde J, Lin W, Xue C, Williams BA, Zaleski C, Roder M, Kokocinski F, Abdelhamid RF, Alioto T, Antoshechkin I, Baer MT, Batut P, Bell I, Bell K, Chakrabortty S, Chrast J, Curado J, Derrien T, Drenkow J, Dumais E, Dumais J, Duttagupta R, Fastuca M, Fejes-Toth K, Ferreira P, Foissac S, Fullwood MJ, Gao H, Gonzalez D, Gordon A, Howald C, Jha S, Johnson R, Kapranov P, King B, Kingswood C, Li G, Luo OJ, Park E, Preall JB, Presaud K, Ribeca P, Robyr D, Ruan X, Sammeth M, Sandu KS, Schaeffer L, See LH, Shahab A, Skancke J, Suzuki AM, Takahashi H, Tilgner H, Trout D, Walters N, Wang H, Hayashizaki Y, Reymond A, Antonarakis SE, Hannon GJ, Ruan Y, Carninci P, Sloan CA, Learned K, Malladi VS, Wong MC, Barber GP, Cline MS, Dreszer TR, Heitner SG, Karolchik D, Kirkup VM, Meyer LR, Long JC, Maddren M, Raney BJ, Grasfeder LL, Giresi PG, Battenhouse A, Sheffield NC, Showers KA, London D, Bhinge AA, Shestak C, Schaner MR, Kim SK, Zhang ZZ, Mieczkowski PA, Mieczkowska JO, Liu Z, McDaniell RM, Ni Y, Rashid NU, Kim MJ, Adar S, Zhang Z, Wang T, Winter D, Keefe D, Iyer VR, Sandhu KS, Zheng M, Wang P, Gertz J, Vielmetter J, Partridge EC, Varley KE, Gasper C, Bansal A, Pepke S, Jain P, Amrhein H, Bowling KM, Anaya M, Cross MK, Muratet MA, Newberry KM, McCue K, Nesmith AS, Fisher-Aylor KI, Pusey B, DeSalvo G, Parker SL, Balasubramanian S, Davis NS, Meadows SK, Eggleston T, Newberry JS, Levy SE, Absher DM, Wong WH, Blow MJ, Visel A, Pennachio LA, Elnitski L, Petrykowska HM, Abyzov A, Aken B, Barrell D, Barson G, Berry A, Bignell A, Boychenko V, Bussotti G, Davidson C, Despacio-Reyes G, Diekhans M, Ezkurdia I, Frankish A, Gilbert J, Gonzalez JM, Griffiths E, Harte R, Hendrix DA, Hunt T, Jungreis I, Kay M, Khurana E, Leng J, Lin MF, Loveland J, Lu Z, Manthravadi D, Mariotti M, Mudge J, Mukherjee G, Notredame C, Pei B, Rodriguez JM, Saunders G, Sboner A, Searle S, Sisu C, Snow C, Steward C, Tapanari E, Tress ML, van Baren MJ, Washieti S, Wilming L, Zadissa A, Zhengdong Z, Brent M, Haussler D, Valencia A, Raymond A, Addleman N, Alexander RP, Auerbach RK, Bettinger K, Bhardwaj N, Boyle AP, Cao AR, Cayting P, Charos A, Cheng Y, Eastman C, Euskirchen G, Fleming JD, Grubert F, Habegger L, Hariharan M, Harmanci A, Iyenger S, Jin VX, Karczewski KJ, Kasowski M, Lacroute P, Lam H, Larnarre-Vincent N, Lian J, Lindahl-Allen M, Min R, Miotto B, Monahan H, Moqtaderi Z, Mu XJ, O’Geen H, Ouyang Z, Patacsil D, Raha D, Ramirez L, Reed B, Shi M, Slifer T, Witt H, Wu L, Xu X, Yan KK, Yang X, Struhl K, Weissman SM, Tenebaum SA, Penalva LO, Karmakar S, Bhanvadia RR, Choudhury A, Domanus M, Ma L, Moran J, Victorsen A, Auer T, Centarin L, Eichenlaub M, Gruhl F, Heerman S, Hoeckendorf B, Inoue D, Kellner T, Kirchmaier S, Mueller C, Reinhardt R, Schertel L, Schneider S, Sinn R, Wittbrodt B, Wittbrodt J, Jain G, Balasundaram G, Bates DL, Byron R, Canfield TK, Diegel MJ, Dunn D, Ebersol AK, Frum T, Garg K, Gist E, Hansen RS, Boatman L, Haugen E, Humbert R, Johnson AK, Johnson EM, Kutyavin TM, Lee K, Lotakis D, Maurano MT, Neph SJ, Neri FV, Nguyen ED, Qu H, Reynolds AP, Roach V, Rynes E, Sanchez ME, Sandstrom RS, Shafer AO, Stergachis AB, Thomas S, Vernot B, Vierstra J, Vong S, Weaver MA, Yan Y, Zhang M, Akey JA, Bender M, Dorschner MO, Groudine M, MacCoss MJ, Navas P, Stamatoyannopoulos G, Stamatoyannopoulos JA, Beal K, Brazma A, Flicek P, Johnson N, Lukk M, Luscombe NM, Sobral D, Vaquerizas JM, Batzoglou S, Sidow A, Hussami N, Kyriazopoulou-Panagiotopoulou S, Libbrecht MW, Schaub MA, Miller W, Bickel PJ, Banfai B, Boley NP, Huang H, Li JJ, Noble WS, Bilmes JA, Buske OJ, Sahu AO, Kharchenko PV, Park PJ, Baker D, Taylor J, Lochovsky L (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414):57–74. doi:10.1038/nature11247

    Article  CAS  Google Scholar 

  5. Fakharzadeh SS, Trusko SP, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo J 10(6):1565–1569

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2(8):912–917

    Article  CAS  PubMed  Google Scholar 

  7. Bartl S, Ban J, Weninger H, Jug G, Kovar H (2003) A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene. Nucleic Acids Res 31(4):1136–1147

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Sam KK, Gan CP, Yee PS, Chong CE, Lim KP, Karen-Ng LP, Chang WS, Nathan S, Rahman ZA, Ismail SM, Cheong SC (2012) Novel MDM2 splice variants identified from oral squamous cell carcinoma. Oral Oncol 48(11):1128–1135. doi:10.1016/j.oraloncology.2012.05.016

    Article  CAS  PubMed  Google Scholar 

  9. Yu Z, Zhang B, Cui B, Wang Y, Han P, Wang X (2012) Identification of spliced variants of the proto-oncogene HDM2 in colorectal cancer. Cancer 118(4):1110–1118. doi:10.1002/cncr.26330

    Article  CAS  PubMed  Google Scholar 

  10. Bartel F, Taylor AC, Taubert H, Harris LC (2001) Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol Res 12(11–12):451–457

    Article  CAS  PubMed  Google Scholar 

  11. Schlott T, Nagel H, Laskawi R, Eiffert H, Droese M (2001) Genetic analysis of the human oncoprotein MDM2 in benign and malignant tumors of the salivary gland. Pathobiology 69(2):67–76

    Article  CAS  PubMed  Google Scholar 

  12. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, Press MF (2001) Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61(7):3212–3219

    CAS  PubMed  Google Scholar 

  13. Hori M, Shimazaki J, Inagawa S, Itabashi M (2000) Alternatively spliced MDM2 transcripts in human breast cancer in relation to tumor necrosis and lymph node involvement. Pathol Int 50(10):786–792

    Article  CAS  PubMed  Google Scholar 

  14. Tamborini E, Della Torre G, Lavarino C, Azzarelli A, Carpinelli P, Pierotti MA, Pilotti S (2001) Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. Int J Cancer 92(6):790–796. doi:10.1002/ijc.1271

    Article  CAS  PubMed  Google Scholar 

  15. Kraus A, Neff F, Behn M, Schuermann M, Muenkel K, Schlegel J (1999) Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. Int J Cancer 80(6):930–934

    Article  CAS  PubMed  Google Scholar 

  16. Arva NC, Talbott KE, Okoro DR, Brekman A, Qiu WG, Bargonetti J (2008) Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis 18(2 Suppl 2):S2-1–8

    Google Scholar 

  17. Bartel F, Meye A, Wurl P, Kappler M, Bache M, Lautenschlager C, Grunbaum U, Schmidt H, Taubert H (2001) Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int J Cancer 95(3):168–175

    Article  CAS  PubMed  Google Scholar 

  18. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G (2001) An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20(30):4041–4049. doi:10.1038/sj.onc.1204533

    Article  CAS  PubMed  Google Scholar 

  19. Anderson JJ, Challen C, Atkins H, Suaeyun R, Crosier S, Lunec J (2007) MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-14. Int J Oncol 31(3):545–555

    CAS  PubMed  Google Scholar 

  20. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H (1998) Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 58(4):609–613

    CAS  PubMed  Google Scholar 

  21. Liang H, Atkins H, Abdel-Fattah R, Jones SN, Lunec J (2004) Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene 338(2):217–223

    Article  CAS  PubMed  Google Scholar 

  22. Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G (2006) Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 66(19):9502–9508. doi:10.1158/0008-5472.CAN-05-4271

    Article  CAS  PubMed  Google Scholar 

  23. Okoro DR, Rosso M, Bargonetti J (2012) Splicing up mdm2 for cancer proteome diversity. Genes Cancer 3(3–4):311–319. doi:10.1177/1947601912455323

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Dias C, Liu Y, Yau A, Westrick L, Evans S (2006) Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Cancer Res 66(19):9467–9473

    Article  CAS  PubMed  Google Scholar 

  25. Dias CS, Liu Y, Yau A, Westrick L, Evans SC (2006) Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Cancer Res 66(19):9467–9473. doi:10.1158/0008-5472.CAN-05-3013

    Article  CAS  PubMed  Google Scholar 

  26. Sanchez-Aguilera A, Garcia JF, Sanchez-Beato M, Piris MA (2006) Hodgkin’s lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. Oncogene 25(18):2565–2574. doi:10.1038/sj.onc.1209282

    Article  CAS  PubMed  Google Scholar 

  27. Weng MW, Lai JC, Hsu CP, Yu KY, Chen CY, Lin TS, Lai WW, Lee H, Ko JL (2005) Alternative splicing of MDM2 mRNA in lung carcinomas and lung cell lines. Environ Mol Mutagen 46(1):1–11. doi:10.1002/em.20118

    Article  CAS  PubMed  Google Scholar 

  28. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23(14):2584–2592

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Busuttil V, Droin N, McCormick L, Bernassola F, Candi E, Melino G, Green DR (2010) NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proc Natl Acad Sci U S A 107(42):18061–18066. doi:10.1073/pnas.1006163107

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Barak Y, Gottlieb E, Juven-Gershon T, Oren M (1994) Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 8:1739–1749

    Article  CAS  PubMed  Google Scholar 

  31. Manfredi J (2010) The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 24(15):1580–1589, 24/15/1580 [pii]. doi:10.1101/gad.1941710

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M, McCormick F (2000) Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103(2):321–330

    Article  CAS  PubMed  Google Scholar 

  33. Slack A, Lozano G, Shohet JM (2005) MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer letters 228(1–2):21–27, S0304-3835(05)00350-2 [pii]. doi:10.1016/j.canlet.2005.01.050

    Article  CAS  PubMed  Google Scholar 

  34. Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, Pollok KE, Boothman DA, Mayo LD (2010) TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest 120(1):290–302. doi:10.1172/JCI39194

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang S, Strong L, Lozano G, Levine A (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5):591–602

    Article  CAS  PubMed  Google Scholar 

  36. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66(10):5104–5110

    Article  CAS  PubMed  Google Scholar 

  37. Xu X, Fang Y, Lee T, Forrest D, Gregory-Evans C, Almeida D, Liu A, Jhanwar S, Abramson D, Cobrinik D (2009) Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 137(6):1018–1031, S0092-8674(09)00400-0 [pii]. doi:10.1016/j.cell.2009.03.051

    Article  CAS  PubMed  Google Scholar 

  38. Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J (2011) A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res: BCR 13(1):R3. doi:10.1186/bcr2804

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Phelps M, Darley M, Primrose JN, Blaydes JP (2003) p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res 63(10):2616–2623

    CAS  PubMed  Google Scholar 

  40. Singh RK, Tapia-Santos A, Bebee TW, Chandler DS (2009) Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress. Exp Cell Res 315(19):3419–3432. doi:10.1016/j.yexcr.2009.07.017

    Article  CAS  PubMed  Google Scholar 

  41. Dutertre M, Sanchez G, De Cian MC, Barbier J, Dardenne E, Gratadou L, Dujardin G, Le Jossic-Corcos C, Corcos L, Auboeuf D (2010) Cotranscriptional exon skipping in the genotoxic stress response. Nat Struct Mol Biol 17(11):1358–1366. doi:10.1038/nsmb.1912

    Article  CAS  PubMed  Google Scholar 

  42. Steinman HA, Burstein E, Lengner C, Gosselin J, Pihan G, Duckett CS, Jones SN (2004) An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 279(6):4877–4886

    Article  CAS  PubMed  Google Scholar 

  43. Volk EL, Schuster K, Nemeth KM, Fan L, Harris LC (2009) MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence. Dis Model Mech 2(1–2):47–55. doi:10.1242/dmm.000992

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Volk EL, Fan L, Schuster K, Rehg JE, Harris LC (2009) The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis. Mol Cancer Res 7(6):863–869. doi:10.1158/1541-7786.MCR-08-0418

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Okoro D, Arva N, Gao C, Polotskaia A, Puente C, Rosso M, Bargonetti J (2013) Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator. PLoS One 8(10):e77643

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Evans S, Viswanathan M, Grier J, Narayana M, El-Naggar A, Lozano G (2001) An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20(30):4041–4049

    Article  CAS  PubMed  Google Scholar 

  47. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299

    Article  CAS  PubMed  Google Scholar 

  48. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fahraeus R, Candeias MM (2009) The p53 mRNA-Mdm2 interaction. Cell Cycle 8(1):31–34

    Article  CAS  PubMed  Google Scholar 

  49. Ghigna C, Valacca C, Biamonti G (2008) Alternative splicing and tumor progression. Curr Genomics 9(8):556–570. doi:10.2174/138920208786847971

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Kalnina Z, Zayakin P, Silina K, Line A (2005) Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42(4):342–357. doi:10.1002/gcc.20156

    Article  CAS  PubMed  Google Scholar 

  51. David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24(21):2343–2364. doi:10.1101/gad.1973010

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Grosso AR, Martins S, Carmo-Fonseca M (2008) The emerging role of splicing factors in cancer. EMBO Rep 9(11):1087–1093. doi:10.1038/embor.2008.189

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463(7279):364–368. doi:10.1038/nature08697

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Chansky HA, Hu M, Hickstein DD, Yang L (2001) Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res 61(9):3586–3590

    CAS  PubMed  Google Scholar 

  55. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H (1998) Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 17(5):603–610. doi:10.1038/sj.onc.1201964

    Article  CAS  PubMed  Google Scholar 

  56. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53(10 Suppl):2231–2234

    CAS  PubMed  Google Scholar 

  57. Hori M, Shimazaki J, Inagawa S, Itabashi M (2002) Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 71(1):77–83

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Sciences, Hunter College, The City University of New York, 695 Park Ave, New York, NY, 10065, USA

    Melissa Rosso, Danielle E. Okoro & Jill Bargonetti

  2. The Graduate Center of the City University of New York, The City University of New York, 695 Park Ave, New York, NY, 10065, USA

    Melissa Rosso, Danielle E. Okoro & Jill Bargonetti

Authors
  1. Melissa Rosso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danielle E. Okoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jill Bargonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jill Bargonetti .

Editor information

Editors and Affiliations

  1. Department of Biochemistry and Molecular Biology, and the Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA

    Swati Palit Deb

  2. Department of Biochemistry and Molecular Biology, and the Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA

    Sumitra Deb

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Rosso, M., Okoro, D.E., Bargonetti, J. (2014). Splice Variants of MDM2 in Oncogenesis. In: Deb, S., Deb, S. (eds) Mutant p53 and MDM2 in Cancer. Subcellular Biochemistry, vol 85. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9211-0_14

Download citation

Publish with us

Policies and ethics

Search

Navigation